PUBLIC COMPANY
save$TEVATEVA PHARMACEUTICAL INDUSTRIES LTD
$TEVA42.57-4.34%Tel Aviv, ILupdated 14h ago
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.
community read0 votes
pipeline
6
marketed
1
phase 3
1
catalysts ytd
10
approvals ytd
4
recalls ytd
3
Pipeline(6)
pipeline depth6 products
3Phase 21Phase 31Marketed1pre_registration
Marketed
omacetaxine mepesuccinate
Myelodysplastic Syndrome (Preleukemia)
Phase 3duvakitug
Crohn's Disease (Regional Enteritis)
Phase 2CEP-11981
Pancreatic Cancer
Vascular endothelial growth factor receptorAngiopoietin-1 receptor
Phase 2TEV-408
Celiac Disease
Phase 2emrusolmin
Multiple System Atrophy (Multi-System Degeneration)
pre_registrationolanzapine ER
Schizophrenia
D2-like dopamine receptor5-hydroxytryptamine receptor 2C
Upcoming
no upcoming catalysts on record
Recent(90d)
view all catalysts →🐶 Hiring Signal
News
- AstraZeneca, Calidi, Tempest make significant workforce cutsFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 18h ago
- Sanofi-backed Windward hits $225M IPO goal, as Rezera delays listing over ‘market conditions’Windward Bio’s IPO has blown to exactly the spot the Swiss biotech had been aiming for, bringing in $225 million to fund a pair of respiratory drugs licensed from China.fiercebiotech · 4d ago
- Blackstone bets $1.5B on Pfizer’s obesity drugThe deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.biopharma_dive · 4d ago
- Sanofi-backed Windward breezes toward $204M IPO to fund respiratory pipeline from ChinaWindward Bio is sailing toward the public markets with the aim of raising over $200 million in proceeds to fund two respiratory drugs licensed from China.fiercebiotech · 8d ago
- Novartis ends BioArctic pact; Two VC firms raise inaugural fundsPlus news about Teva, Ultragenyx and Specific Biologics. Novartis cans BioArctic collab: The Swiss pharma axed its discovery-stage work with the Swedish biotech, which created the Alzheimer’s drug…endpoints · 13d ago
- UniQure gets an FDA decision date; Teva scraps brain drug studyThe FDA appears likely to hold an advisory committee for UniQure’s closely watched Huntington’s disease gene therapy. Elsewhere, a biotech’s share price was cut in half following a regulatory setback.biopharma_dive · 13d ago
- Teva ends trial of one of its original line-up of innovative meds over futilityTeva has given up on a key trial of one of its original line-up of innovative medicines.fiercebiotech · 15d ago
- UK lands £500M in biopharma pledges; Teva to shutter New Jersey sitePlus, news about Esteve and Regeneron. UK pulls in £500M investment: As part of the UK’s Autumn budget, Vertex Pharmaceuticals said it will invest over £300 million in a new R&D site in Oxford, UK ...endpoints · 18d ago
- Webinar: The China question: Can US biotechs lead as investment heads east?In this webinar, BioSpace will gathered experts to discuss China’s impact on the future of biotech and how both U.S. and Chinese companies can thrive—and maybe even collaborate.biospace · 1mo ago
- First Tracks climbs on ‘impressive’ celiac study dataInitial study findings strengthened some analysts’ belief that First Tracks’ drug, one of a few in development aimed at the protein CD122, might have “pipeline-in-a-product” potential.biopharma_dive · 1mo ago
Data sources
last refreshed 50m ago
Found something off?
comments(0)
5-min edit window · permanent after that